Cephalon/Lundbeck Discontinue Phase II/III Parkinson’s Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
The compound CEP-1347 failed to demonstrate efficacy over placebo, a data monitoring committee determined. The mixed-lineage oral kinase apoptosis inhibitor was thought to prevent neuronal apoptosis. Novartis also discontinued development of a similar Phase II agent.